HSP90:Buffering and Drug Resistance
- Detailed Technology Description
- None
- *Abstract
-
Whitehead Intellectual Property Office is seeking a licensee for the invention, ΓÇ£HSP90:Buffering and Drug ResistanceΓÇØ. Invasive fungal infections are a leading cause of mortality among immunocompromised individuals. Treatment is notoriously difficult with the limited cadre of antifungal drugs, whose efficacy is compromised by host toxicity, a limited activity spectrum, or the emergence of drug resistance. Researchers at the Whitehead Institute have established that the molecular chaperone Hsp90 enables the emergence and maintenance of fungal drug resistance. They have developed a method of reducing fungal drug resistance by reducing the function of an appropriate heat shock protein in the fungus- coadministration of an antifungal and an HSP inhibitor.
- Country/Region
- USA
For more information, please click Here
